AA
MITO

AlphaMark Advisors’s Stealth BioTherapeutics Corp. ADS MITO Stock Holding History

AlphaMark Advisors’s Portfolio MITO Stock Details MITO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-2,306
Closed -$1K – 759
2022
Q3 		$1K Hold
2,306
– – ﹤0.01% 679
2022
Q2 		$1K Hold
2,306
– – ﹤0.01% 621
2022
Q1 		$2K Hold
2,306
– – ﹤0.01% 566
2021
Q4 		$2K Hold
2,306
– – ﹤0.01% 537
2021
Q3 		$3K Buy
+2,306
New +$3.13K ﹤0.01% 520

AlphaMark Advisors's MITO Position: Q4 2022 in Review

AlphaMark Advisors sold out of Stealth BioTherapeutics Corp. ADS (MITO) in Q4 2022, closing a stake of 2,306 shares — an estimated $1K sold.

AlphaMark Advisors first reported a position in MITO in Q3 2021 and held it in 5 quarters. The position peaked at $3K in Q3 2021. 0 funds tracked by Wall St. Rank hold MITO as of Q4 2022.

  • AlphaMark Advisors reported no remaining Stealth BioTherapeutics Corp. ADS position as of Q4 2022 after selling out during the quarter.
  • AlphaMark Advisors sold 2,306 Stealth BioTherapeutics Corp. ADS shares in Q4 2022, an estimated $1K.
  • AlphaMark Advisors first reported a position in Stealth BioTherapeutics Corp. ADS in Q3 2021 and held it in 5 quarters.
  • AlphaMark Advisors's Stealth BioTherapeutics Corp. ADS position peaked at $3K in Q3 2021.
  • 0 funds tracked by Wall St. Rank held Stealth BioTherapeutics Corp. ADS as of Q4 2022.

Based on AlphaMark Advisors's 13F filing for Q4 2022, filed 6 Feb 2023.